Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
4.010
+0.060 (1.52%)
At close: Nov 28, 2025, 1:00 PM EST
3.990
-0.020 (-0.50%)
After-hours: Nov 28, 2025, 4:59 PM EST

Esperion Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
944433340459306725
Upgrade
Market Cap Growth
97.18%27.49%-25.93%49.97%-57.77%-55.52%
Upgrade
Enterprise Value
1,453848757815726687
Upgrade
Last Close Price
4.012.202.996.235.0026.00
Upgrade
Forward PE
13.2816.60----
Upgrade
PS Ratio
2.611.302.926.083.903.19
Upgrade
PB Ratio
--1.11-0.75-1.42-1.55-7.54
Upgrade
EV/Sales Ratio
4.782.556.5110.799.263.02
Upgrade
EV/EBITDA Ratio
-15.58----
Upgrade
EV/EBIT Ratio
-15.59----
Upgrade
Debt / Equity Ratio
-1.33-1.52-1.19-1.56-2.63-3.77
Upgrade
Debt / EBITDA Ratio
-10.29----
Upgrade
Asset Turnover
0.901.210.510.240.210.80
Upgrade
Inventory Turnover
1.551.432.574.194.76-
Upgrade
Quick Ratio
0.590.910.842.173.853.37
Upgrade
Current Ratio
1.001.371.292.674.493.68
Upgrade
Return on Assets (ROA)
-5.42%12.37%-42.86%-35.64%-36.31%-26.73%
Upgrade
Return on Capital (ROIC)
-10.83%23.58%-72.90%-44.78%-45.52%-36.13%
Upgrade
Return on Capital Employed (ROCE)
-589.10%55.70%-313.80%-115.30%-69.30%-46.80%
Upgrade
Earnings Yield
-11.21%-11.94%-61.54%-50.90%-87.91%-19.81%
Upgrade
FCF Yield
-9.88%-5.53%-39.85%-38.09%-86.18%-11.87%
Upgrade
Buyback Yield / Dilution
-18.70%-81.54%-55.26%-129.76%-5.20%-1.42%
Upgrade
Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q